Clinical trial
Leprosy Skin Test Antigens Trial
NCT00128193 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00128193 |
|---|---|
| Title | Leprosy Skin Test Antigens Trial |
| Official title | Two New Leprosy Skin Test Antigens: MLSA-LAM and MLCwA Phase II Study in a Leprosy-Endemic Region |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leprosy |
| Intervention type | Biological, Other |
| Interventions | Tuberculin, Purified Protein Derivative, MLSA-LAM, MLCwA, Placebo |
| Enrollment | 260 |
| Start date | Apr 1, 2002 |
| Primary completion | Sep 1, 2009 |
| Completion | Sep 1, 2009 |
| First posted | Aug 9, 2005 |
| Last update posted | Dec 24, 2014 |
| Countries | Nepal, United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: